Dr. Reddy’s Q1 FY27 Results: Base Business Remains Strong Despite Semaglutide-Related Impact on Margins

What Happened ?

key details

Base Business Delivered Healthy Double-Digit Growth:

Despite the reported decline in profitability due to semaglutide API-related charges, Dr. Reddy’s underlying business continued to expand across key therapeutic segments and international markets. Excluding the one-time impact, the company delivered healthy operational performance supported by new product launches, favorable foreign exchange movements and sustained demand across geographies. 

Geographic Performance:

The company reported broad-based growth across most major markets, reflecting continued execution of its diversified global business strategy.

• India
  • Revenue increased 12% year-on-year.
  • Growth was supported by new product launches, stronger prescription demand and expansion of the nutrition portfolio.
  • Generic Semaglutide tablets were launched in India during the quarter.

• North America
  • Base business recorded healthy double-digit growth.
  • Performance benefited from new product launches and favorable foreign exchange movements.
  • Growth was partly offset by lower contribution from Revlimid and the semaglutide API-related impact.
  • The company secured 180-day exclusivity for the launch of generic Bosutinib 400 mg tablets in the United States.

• Europe
  • Revenue increased on the back of new product launches and stable demand across established generic products.
  • Continued expansion of the commercial portfolio supported growth during the quarter. 

• Emerging Market
  • Continued healthy growth driven by branded generics across multiple international markets.
  • Strong momentum was reported across several therapeutic categories supported by expanding market presence.

Product Launches and Pipeline Progress:

Dr. Reddy’s continued strengthening its portfolio through new launches, regulatory approvals and specialty product expansion.

Key Highlights:

• Launched the first generic Semaglutide injection for Type 2 Diabetes in Canada.
• Introduced generic Semaglutide tablets in India.
• Received 180-day exclusivity for generic Bosutinib 400 mg tablets in the United States.
• Expanded its nutrition portfolio through Celevida GLP+, developed in collaboration with Nestlé Health Science.
• Continued advancing multiple differentiated products and complex generic opportunities across global markets. 

Research, Development and Strategic Initiatives:

The company continued investing in innovation, specialty medicines and strategic collaborations to strengthen its long-term growth pipeline.

Key Highlights

• Continued development of complex generics and specialty pharmaceutical products.
• Expanded strategic partnerships to accelerate innovation across key therapeutic areas.
• Maintained focus on differentiated products with higher entry barriers.
• Continued investments in research, regulatory filings and product development across global markets.
• Strengthened commercialization capabilities across regulated and emerging markets. 

Operational Developments:

Alongside commercial execution, the company continued strengthening its manufacturing and supply chain capabilities while navigating temporary cost pressures.

Key Highlights

• Reported a ₹240 crore one-time semaglutide API-related impact comprising inventory provisions and associated costs.
• Freight expenses increased due to geopolitical disruptions in the Middle East.
• Higher solvent costs also affected gross margins during the quarter.
• Despite these headwinds, management indicated that the core operating business remained resilient and delivered healthy double-digit growth excluding the one-time impacts.
• The company maintained a net cash surplus of ₹3,058 crore, providing financial flexibility to support future investments and business expansion.

Note:

• Management emphasized that the profitability impact during Q1 FY27 was largely attributable to temporary semaglutide API-related provisions and elevated logistics costs rather than weakness in the underlying pharmaceutical business.
• The company’s diversified portfolio, ongoing product launches and continued investment in innovation support its long-term growth strategy.

Risk Analysis

Summary:

• Dr. Reddy’s delivered resilient underlying business growth during Q1 FY27, but reported profitability was affected by one-time semaglutide API-related inventory provisions and higher logistics costs. Going forward, execution of complex product launches, stabilization of margins and sustained growth across key international markets will remain important factors influencing financial performance. 

Key Risks:

• The ₹240 crore semaglutide API-related impact reduced reported profitability during the quarter, highlighting execution risks associated with complex pharmaceutical products.
• Elevated freight and logistics costs arising from geopolitical disruptions may continue to pressure margins if supply chain conditions remain volatile.
• Revenue from certain high-value generic products may fluctuate due to pricing pressure, competition and exclusivity timelines in regulated markets.
• Pharmaceutical businesses remain exposed to regulatory inspections, product approval timelines and manufacturing compliance across global markets.
• Currency movements, raw material prices and competitive pricing in generic medicines could affect future earnings.

Worst Case:

• If additional inventory-related provisions arise, logistics disruptions persist or competition intensifies in key generic products, profitability could remain under pressure despite continued growth in the company’s underlying business.

Risk Level: Medium

Company Commentary

• Erez Israeli, Chief Executive Officer, Dr. Reddy’s Laboratories, said the company delivered healthy double-digit growth in its underlying base business during the quarter despite temporary profitability pressures from the semaglutide API-related impact.
• Management stated that excluding the one-time semaglutide-related charges, the company’s operating performance remained robust, supported by growth across major markets and continued execution of strategic priorities.
• The company highlighted important product milestones during the quarter, including the launch of the first generic semaglutide injection in Canada, introduction of generic semaglutide tablets in India, and receipt of 180-day exclusivity for generic Bosutinib 400 mg in the United States.
• Management reiterated its commitment to strengthening its portfolio through innovation, differentiated products, specialty medicines and continued investment in research and global market expansion.